New studies have demonstrated that inhibiting GLRX5 induces ferroptosis in cisplatin-resistant head and neck cancer cells, suggesting a new therapeutic strategy for overcoming head and neck cancer chemoresistance through promoting ferroptosis by inhibiting GLRX5 [83]. Here, GLRX5 is linked to head and neck cancer.